A Phase II Dose-ranging Study of Oral RV3-BB Rotavirus Vaccine

Inclusion Criteria: * Neonate is less than 6 days (≤144 hours) of age at the time of first dose. * Neonate is in good health as determined by clinical judgment, including a medical history and physical exam, which confirms the absence of a current or past disease state considered significant by the investigator. * Neonate birth weight 2500-4000g inclusive. * Neonate's parents/guardians expect to be available for the duration of the study, and agree to adhere to all protocol requirements. * Neonate's parents/guardians have provided written informed consent prior to study-related procedures being performed. Exclusion Criteria: * Any medical, psychiatric, or social condition of a parent/guardian that in the opinion of the investigator would prevent the neonate's parents/guardians from giving proper informed consent or from complying with the study protocol. * Neonates with known or suspected major congenital malformations or genetically determined disease. * Neonates with intussusception. * Neonates with a known or suspected bleeding diathesis, or any condition that may be associated with a prolonged bleeding time. * Neonates who have ever received any blood products, including immunoglobulin, or for whom receipt of any blood product during the course of the study is anticipated. * Neonates in whom Essential Programme Immunisation (EPI) vaccines or components are contraindicated. * Neonates who have received or who expect to receive during the study period, any rotavirus vaccine other than those which will be administered as part of this study. * Neonates who have ever received, or who are anticipated to receive during the study period, any investigational agent other than those which will be administered as part of this study. * Neonates with a previous anaphylactic reaction to any drug, vaccine or vaccine component. * Neonates with a significant evolving neurological disorder. * Neonates whose parents/guardians are site team employees with direct involvement with the investigators, or who are working on the study. * Neonates who have been exposed to immunosuppressive courses of glucocorticosteroids, cytotoxic drugs or blood products through prenatal exposure and/or breast milk in the four weeks prior to randomization. * Neonates with diarrhoea or vomiting in the 24 hours preceding randomisation. * Neonates with any moderate or severe illness, and/or who have a temperature of ≥37.5˚C axillary/oral or ≥38˚C rectal/tympanic within the 48 hours preceding randomization.